CAMBRIDGE, Mass. — The landscape of genetic medicine shifted significantly this morning as the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EDIT-103 , an experimental in-vivo gene editing therapy developed by Editas Medicine.
The announcement, made early Thursday, sent biotechnology stocks rallying as it marks a pivotal step toward curing Leber Congenital Amaurosis (LCA), a rare genetic condition that causes blindness in children.
The Breaking News Unlike previous treatments that require removing cells from the body, editing them in a lab, and re-infusing them (ex-vivo), EDIT-103 is injected directly into the patient’s retina. The therapy uses a proprietary CRISPR-Cas9 complex to snip out the specific genetic mutation responsible for the disease.
“This designation is not just a regulatory milestone; it is a recognition of the transformative potential of in-vivo editing,” said Dr. Elena Rossi, Chief Medical Officer at Editas, in a press conference held at 9:00 AM EST today. “Our Phase 1/2 data indicates that 40% of participants experienced a clinically meaningful improvement in visual acuity within three months of dosing.”
Clinical Trial Results The data released alongside the announcement highlights three key findings from the ongoing “BRILLIANCE” trial:
Safety: No serious adverse events or immune rejections were reported in the high-dose cohort.
Efficacy: Two patients who were previously legally blind are now able to navigate a maze in low-light conditions.
Durability: The genetic correction appears stable, with the first patient dosed showing sustained improvement 12 months post-treatment.
Market & Industry Reaction Following the news, shares of Editas Medicine (EDIT) surged 14% in pre-market trading. Analysts suggest that this success could pave the way for similar “direct-to-patient” gene editing therapies for other organs, such as the heart and brain, which have historically been difficult to treat.
The company plans to initiate a pivotal Phase 3 trial by Q2 2026.
